In episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Pharma, about its strategy and work in the rare diseases and gene therapy space.
Pfizer plans to raise the prices of 41 prescription drugs in January, despite falling foul of President Trump, who criticised the company’s stance on costs earlier this summer.
GlaxoSmithKline plans to carry out clinical trials on its pancreatic drug hopeful, GSK547, following promising results when treating mice and laboratory-grown tumour cells.
AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payme
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
